1. Home
  2. ESAB vs GKOS Comparison

ESAB vs GKOS Comparison

Compare ESAB & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ESAB Corporation

ESAB

ESAB Corporation

HOLD

Current Price

$111.94

Market Cap

6.4B

Sector

Industrials

ML Signal

HOLD

Logo Glaukos Corporation

GKOS

Glaukos Corporation

HOLD

Current Price

$110.90

Market Cap

5.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ESAB
GKOS
Founded
1904
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Office Equipment/Supplies/Services
Medical/Dental Instruments
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.4B
5.4B
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
ESAB
GKOS
Price
$111.94
$110.90
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
13
Target Price
$140.38
$126.38
AVG Volume (30 Days)
459.4K
670.7K
Earning Date
02-19-2026
02-19-2026
Dividend Yield
0.36%
N/A
EPS Growth
N/A
N/A
EPS
3.95
N/A
Revenue
$2,792,325,000.00
$469,820,000.00
Revenue This Year
$3.25
$31.15
Revenue Next Year
$8.37
$24.15
P/E Ratio
$28.29
N/A
Revenue Growth
1.19
30.38
52 Week Low
$100.17
$73.16
52 Week High
$135.84
$163.71

Technical Indicators

Market Signals
Indicator
ESAB
GKOS
Relative Strength Index (RSI) 45.51 54.19
Support Level $111.25 $115.07
Resistance Level $114.80 $117.94
Average True Range (ATR) 2.41 2.72
MACD -0.22 -1.05
Stochastic Oscillator 6.52 22.33

Price Performance

Historical Comparison
ESAB
GKOS

About ESAB ESAB Corporation

ESAB, spun off from Colfax in 2022, is a leading manufacturer of equipment and consumables used in welding, cutting, and joining applications. Alongside competitors Lincoln Electric and ITW's Miller brand, ESAB is one of the top three players in the welding space. ESAB generated roughly $2.7 billion in revenue in 2024.

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Share on Social Networks: